Conditions: Myeloid Leukemia, Chronic, Chronic-Phase
Keywords: Chronic Phase Chronic Myelogenous Leukemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 724
Healthy volunteers: no

Brief summary:
This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: dasatinib intervention 2: dasatinib intervention 3: dasatinib intervention 4: dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, 50 mg BID, indefinitely, survival study intervention 2: Tablets, Oral, 70 mg BID, indefinitely, survival study intervention 3: Tablets, Oral, 100 mg QD, indefinitely, survival study intervention 4: Tablets, Oral, 140 mg QD, indefinitely, survival study

Protocol document: